Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.